Acute Myelogenous Leukemia

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT

By

The most frequently observed adverse events among patients treated with sorafenib were cytopenias and skin rashes.

Attacking Acute Myelogenous Leukemia (AML) in a New Way: Early Results for AG-221 Show Promise

Attacking Acute Myelogenous Leukemia (AML) in a New Way: Early Results for AG-221 Show Promise

By

There is warranted excitement for AG-221, a drug recently granted fast track designation by the FDA for acute myelogenous leukemia (AML).

FDA Fast Tracks AG-221 to Treat AML

FDA Fast Tracks AG-221 to Treat AML

The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.

Biomarkers, AlloHSCT Predict Post-AML Relapse Prognosis

By

Cytogenetic and molecular abnormalities may also be prognostic of post-relapse prognosis.

Drug Could Improve Outcomes for Children with High-Risk Leukemia

Results from a new study could benefit some children with high-risk AML. A therapeutic regimen that combined the GO with conventional three-drug chemotherapy was associated with improved survival in children with AML who underwent bone marrow transplantation.

Researchers ID Average of 13 Mutations in Adult AML Genomes

Researchers ID Average of 13 Mutations in Adult AML Genomes

At least one nonsynonymous mutation in a gene relevant for pathogenesis seen in nearly all cases

Flow Cytometry Indicates Treatment Response in AML

Flow Cytometry Indicates Treatment Response in AML

Assessment of minimal residual disease provides prognostic information for children with AML.

Additional Mutations Identified in Relapse-Specific AML

Additional Mutations Identified in Relapse-Specific AML

Relapse of acute myeloid leukemia (AML) is associated with acquisition of new mutations and clonal evolution.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs